Bone disease in uremic patients: Advances in PTH suppression

Journal of Nephrology

Volumn 15, Issue SUPPL. 6, 2002, Pages

  Brancaccio, Diego ^a   Cozzolino, Mario ^a   Gorio, Alfredo ^b   Di Giulio, Anna Maria ^b   Gallieni, Maurizio ^a  

^a Ospedale San Paolo   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Analogs; Calcimimetic; Dialysis; Hyperparathyroidism; Renal osteodystrophy; Vitamin D

Indexed keywords

22 OXACALCITRIOL; CALCIMIMETIC AGENT; CALCITRIOL; DOXERCALCIFEROL; ERGOCALCIFEROL; OXYGENASE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; VITAMIN D;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HYPERPARATHYROIDISM; INTESTINE ABSORPTION; MEDICAL RESEARCH; METABOLITE; RENAL OSTEODYSTROPHY; REVIEW; UREMIA; BONE DISEASE; DRUG ANTAGONISM; PATHOPHYSIOLOGY;

BONE DISEASES; HUMANS; HYPERPARATHYROIDISM; PARATHYROID HORMONE; UREMIA;

EID: 0036877372     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Chesney RW, Hamstra AJ, Mazess RB. Circulating vitamin D metabolite concentrations in childhood renal disease. Kidney Int 1997;21:65-72.
2. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11 (suppl 3): S130-5.
3. Slatopolsky E, Finch J, Denda M. Phosphorous restriction prevents parathyroid gland growth: High phophorom directly stimulates PTH secretion IH vitro. J Clin Invest 1996; 97: 2534-40.
4. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate and vitamin D. J Clin Invest 1995; 96: 1786-93.
5. Dusso AS, Pavlopoulos T, Naumovich L. p21 (WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 2001; 59: 855-65.
6. WAFI and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001; 60: 2109-17.
7. Brown AJ. Vitamin D analogues. Am J Kidney Dis 1998; 32 (suppl 2): S25-S39.
8. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999; 277: F157-F175.
9. Reichel H, Deibert B, Schmidt-Gay H, Ritz E. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991; 6: 162-9.
10. Malluche HH, Monier-Faugerc MC. Understanding and managing hyperphosphatemia in patients with chronic renal disease. Clin Nephrol 1999; 52: 267-77.
11. Malluche HH, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211.
12. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11: 130-5.
13. Malluche HH, Matthews C, Faugere MC. 1,25-dihydroxvitamin D maintains bone cell activity, and parathyroid hormone modulates bone cell number in dogs. Endocrinology 1986; 119: 1298-304.
14. Baker LR, Abrams L, Roe CJ. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-9.
15. Hamdy NA, Kanis JA, Beneton MN. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 1995; 310: 358-63.
16. Gallieni M, Brancaccio D, Padovese P. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992; 42: 1191-8.
17. Pei Y, Hercz G, Greenwood C. Risk factors for renal ostcodystrophy: a multivariant analysis. J Bone Miner Res 1995; 10: 149-56.
18. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999; 56 (suppl 73): S14-19.
19. Arnold A, Brown MF, Urena P. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-53.
20. Fukuda N, Tanaka H, Tominaga Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-43.
21. Shuopolsky E, Weerts C, Thielan J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25- dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-43.
22. Cozzolino M, Dusso A, Slatopolsky E. Role of calcium × phosphate product and bone associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001; 12: 2511-16.
23. Brancaccio D, Tetta C, Gallieni M, Panichi V. Inflammation, CRP, calcium overload and a high calcium-phosphate product: a "liaison dangereuse". Nephrol Dial Transplant 2002; 17: 201-3.
24. Delmez JA, Tindira C, Grooms P. Parathyroid hormone suppression by intravenous 1,25(OH)2D: a role for increased sensitivity to calcium. J Clin Invest 1989; 83: 1349-55.
25. Llach F. Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. Kidney Int 1999; (suppl 73): S31-S37.
26. Llach F, Yudd M. The importance of hyperphosphatemia in the severity of hyperparathyroidism and its treatment in patients with chronic renal failure. Nephrol Dial Transplant 1998; 13: 57-61.
27. Slatopolsky E, Dusso A, Brown A. New analogs of Vitamin D3. Kidney Int 1999; 56 (suppl 73): S46-51.
28. Bouillon R, Okaimira WH, Norman AW. Structure-function relationship in the vitamin D endocrine system. Endocrinol. Rev 1995; 16: 2001-57.
29. Morinier-Faugere MC, Geng Z, Friedler RM. 22-Oxacalcitriol suppresses secondary hyperparatliyroidism without inducing low bone turnover in clogs with renal failure. Kidney Int 1999; 55: 821-32.
30. Azikawa T, Suzuki M, Akiba T. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001; 38 (suppl 1): S147-S151.
31. Martin KJ, Gonzales EA, Gellens M. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-32.
32. Takahashi F, Finch JL, Denda M. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30: 105-12.
33. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorous resorption in bone. J Am Soc Nephrol 1999; 10: 980-5.
34. Sprague SM, Lerma E, McCormmick D. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001; 38: S51-56.
35. Sjoden G, Smith C, Lindgren U, De Luca HF. 1 alpha-hydroxyvitamin D2 is less toxic then 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985; 178: 432-6.
36. Maung HM, Elangovan L, Frazao J. Efficacy and side effects of intermittent intravenous and oral doxercalciferol 1 alpha (OH)D2 in dialysis patients with secondary hyperparatliyroidism: A sequential comparison. Am J Kidney Dis 2001; 37: 537-43.
37. Sasaki H, Harada H, Handa Y. Transcritpional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. Biochemistry 1995; 34: 370-7.
38. Akiba T, Marumo F, Owada A. Controlled trial of falecalciferol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998; 32: 238-46.
39. ++-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-80.
40. ++ and other ions as extracellular (first) messengers. Physiol Rev 1991; 71: 371-411.
41. Pearce SHS, Trump D, Wooding C. Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J Clin Invest 1995; 96: 2683-92.
42. Pollak MR, Brown EM, Chou Y-HW. Mutations in the human Ca++-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe-hyperparathyroidism. Cell 1993; 75: 1297-303.
43. Pollak MR, Seidman CE, Brown EM. Three inherited disorders of calcium sensing. Medicine (Baltimore) 1996; 75: 115-23.
44. Baron J, Winer KK, Yanoski JA. Mutations of the Ca++ sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism Hum Mol Genet 1996; 5: 601-6.
45. Pearce SHS, Williamson C, Kifor O. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J. Med 1996; 335: 1115-22.
46. Brown EM, Pollak M, Hebert SC. The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 1998; 49: 15-29.
47. Brown EM. Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am J Med 1999; 106: 238-53.
48. Goodmann WG, Frazao JM, Goodkin DA. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-45.
49. Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997; 20: 303-9.
50. Coburn JW, Barri YM, Turner SA. Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2000; 11: 573A.
51. Goodman WG, Hladik GA, Turner SA. Multiple doses of the calcimimetic AMG 073 reduce parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (SHPT). J Am Soc Nephrol 2000; 11: 576A.
52. Lindberg JS, Moe SM, Goodman WG. The calcimimetic AMG 073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium × phosphorus product (Ca × P) in patients with ERSD and secondary hyperparathyroidism. J Am Soc Nephrol 2000; 11: 578A.
53. Quarles LD, Sherrard DJ, Adler S. The calcimimetic AMG 073 reduces PTH and Ca × P in patients with secondary hyperparathyroidism. J Am Soc Nephrol 2001; 12: 763 A.
54. Drucke T, Cunningham J, Goodman WG. Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073. J Am Soc Nephrol 2001; 12: 764 A.